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Cost^e¡ectiveness of salmeterol in patients with
chronic obstructive pulmonary disease:
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Abstract Chronicobstructive pulmonarydisease (COPD) is associatedwith a large economic and socialburden.Few
economic studies have examined the benefits of inhaled therapy for patientswith COPD.This16-week studyexamined
the cost^effectiveness of salmeterolinthispatientgroup.Patientswith ahistoryof COPDwererandomisedtotreatment
with salmetrol 50mcg (229 patients) or placebo (227 patients) twice daily, administered bymetered-dose inhaler in ad-
ditiontonormaltherapy.Forcedexpiratory volume (FEV1)wasmeasuredandpatientsrecordedtheimpactoftheir symp-
toms in a daily diary.Health statuswas assessed using the St George’s Respiratory Questionnaire. A significantly higher
proportion of salmeterol-treated patients had an increase of415% in FEV1. Salmeterol patients had a highermean pro-
portion of symptom-free days and nights than those in the placebo group.More salmeterol patients had a clinically sig-
nificant improvement inhealth status.Totalhealthcare costswere increasedinthe salmeterolgroup, buthospital and GP
visit costs and concurrent COPDmedication costs were lower.The reduction in hospital costs was sufficient to offset a
substantial portion of the acquisition cost of salmeterol. Addition of salmeterol to COPD patients’ current therapy
improved lung function, health status at the expense of a modest increase in costs compared with usual therapy.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Chronic obstructive pulmonary disease (COPD) is a dis-
ease characterised by the presence of air£ow obstruc-
tion due to chronic bronchitis, emphysema and airway
obstruction that has both ¢scal and variable compo-
nents. It is very largely smoking related (1). COPD is
generally characterised by an accelerated loss of
lung function that leads to increasingdisability andhandi-
caps. Pharmacotherapy is one of the mainstays of treat-
ment for COPD. After smoking cessation, the main
pharmacological options are bronchodilators and corto-
costeroids (2).
COPD is caused primarily by exposure to tobacco
smoke. Environmental air pollution and occupationalReceived 5 March 2002, accepted in revised form 23 July 2002.
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E-mail: pjones@sghms.ac.ukfactors are also associated with an increased risk of
COPD, but to a much lesser extent than cigarette smok-
ing.The genetic abnormality, (1-antitrypsin de¢ciency, is
also implicated in COPD (3).Reliable estimates as to the
prevalence and incidence of COPD are rare. In1990, the
mortality rate from COPD was 3.81 per 100 000 in
France (4). Estimates of the prevalence of COPD in the
U.S.A. vary; however, it is has been estimated that 12.5
million people in the U.S.A. su¡er from chronic bronchi-
tis and1.65 million su¡er from emphysema (1).COPD is a
leading cause of death worldwide (5), and in1985 COPD
was an underlying cause for 3.6% of all deaths and a con-
tributory factor in 4.3% of deaths. The incidence of
COPD is increasing; between 1982 and 1995, the esti-
mated number of people with COPD has increased by
over 40% (4).
COPD is a signi¢cant economic and social burden for
society.The cost of caring for COPD has been reported
to be $40 billion per year in theU.S.A.withbetween $1.4
and $3 billion attributed to home oxygen therapy (6). In
TABLE 1. Baseline patient characteristics by treatment
group
Salmeterol
50mcg
Placebo P-value
No. of patients 229 227
Age: mean (SD) 63 (8) 62 (8) 0.17
Gender:No. (%) male 189 (83) 171 (75)
FEV1 (l): mean (SD) 1.31 (0.51) 1.31 (0.53) 0.96
FEV1% predicted: mean (SD) 45.3 (15.9) 45.4 (15.3) 0.98
SGRQ (domain scores)
No. of patients 94 95
Symptoms: mean (SD) 67 (20) 68 (19) 0.89
Activities: mean (SD) 65 (21) 64 (23) 0.61
Impacts: mean (SD) 45 (19) 46 (21) 0.11
Total: mean (SD) 54 (17) 52 (18) 0.20
ECONOMICEVALUATIONOFSALMETEROLINCOPD 21the U.K., 25% of primary care physician visits are due to
respiratory disease and 28 million lost working days and
5% of deaths have been attributed to chronic bronchitis
(7). Due to the considerable burden on patients, care-
givers and the healthcare system, there has been an in-
terest in evaluating therapies that o¡er substantial
clinical bene¢ts while simultaneously addressing changes
in total directmedical costs.Reimbursement authorities
across Europe andNorthhave sought to rationalise their
spending on pharmaceutical agents by adopting guide-
lines that encourage the identi¢cation of cost^ e¡ective
products. Cost^ e¡ectiveness analyses evaluate the net
changes in costs and outcomes thatwill result fromusing
a new treatment in a particular group of patients, com-
pared with an existing treatment. In particular, where
the drug is more expensive, it is necessary to determine
whether the increase in cost is justi¢ed by the resultant
improvement in clinicallymeaningful outcomes.
The long-acting inhaledbronchodilator, salmeterol has
been shown to be signi¢cantlybetter thanplacebo in im-
proving lung function, improving symptom scores, and
health status (8,9).The aim of the present study was to
analyse data obtained during a randomised-controlled
trial of the clinical e⁄cacy of salmeterol (9,10) to quantify
the cost^ e¡ectiveness of salmeterolwhen added to nor-
mal therapy compared to normal therapy in patients
with COPD.We also wished to determine whether or
not the additional drug treatment costs are justi¢ed by
additional clinical bene¢ts and reduced utilisation of
other healthcare resources.
MATERIALSANDMETHODS
Patients
Full details of this study have been published previously
(9,10). Patients with a diagnosis of COPD were recruited
in 75 centres in17 countries.Male and femalepatientsbe-
tween the ages of 40 and 75 years were included in the
study if they were current or previous smokers with a
history of smoking equivalent to 10 pack years. All pa-
tients had coughed up sputum on most days during at
least 3 consecutivemonths in 2 consecutive years.
Patients enrolled in the study were evaluated during a
2-week run-in period prior to the initiation of study
treatment. During this period patients had to demon-
strate a forced expiratory volume in1s ( FEV1) less than
or equal to 70% of predicted normal values but greater
than 0.6 l. The use of bronchodilators was withheld for
4h prior to the measurement of FEV1. Patients also had
to demonstrate a FEV1/forced vital capacity (FVC) ratio
of less than or equal to 60%. Reversibility had to be de-
monstrated by one of three methods: (1) an increase in
FEV1of between 5 and15%,15min after the inhalation of
400 mcg /800mcg salbutamol from a MDI/Disk inhaler,
or (2) FEV1had to increase by 5^15%,15min after a stan-dard dose of nebulised salbutamol, or (3) there had to be
a documented history of reversibility of between 5 and
15% after an inhaled beta2-agonist from up to12 months
prior to the start of the study.
All patients provided written, informed consent and
the study protocol was approved by the relevant autho-
rities.The study was carried out in accordance with the
Declaration of Helsinki guidelines. Patient characteris-
tics at baseline are shown inTable 1. All patients had to
have recorded, at a minimum, breathlessness at on mild
exertion for at least four of the 7-day run-in period.
Study design
In this double-blind,multicentre, parallelgroup study,pa-
tientswere randomised to receive inhaled salmeterol xi-
nafoate 50mcg twice daily (229 patients), inhaled
salmeterol xinafoate 100mcg twice daily (218 patients)
or placebo twice daily (227 patients) for16weeks in addi-
tion to their standardCOPDtherapy. All agentswere ad-
ministered via a metred-dose inhaler. Patients were
permitted to take other non-agonists prescribed COPD
medications provided that the dose remained constant.
E⁄cacy and safety results for the entire patient popula-
tion have been presentedpreviously (10).
E⁄cacy analyses
The health status analysis of this study showed that only
the 50mcg twice daily dose produced worthwhile clini-
cal bene¢t in terms of improved health status (9). Spiro-
metric bene¢ts were similar with both doses but, in the
case of the higher dose, this was not transformed into
symptomatic bene¢t probably because of increased side
e¡ects (9). Furthermore, only the lower dose is licensed
for use in COPD, so for these reasons this cost^e¡ec-
tiveness analysis was con¢ned to the standard (50mcg
22 RESPIRATORYMEDICINEtwice daily) dose regime in comparisonwith placebo.The
analysis was based on the intent-to-treat (ITT) popula-
tion. E⁄cacy analyses were performed on FEV1, the per-
centage of symptom-free nights, percentage of dayswith
a daytime symptom score less than 2 and health status.
Diary card data were used to derive the ¢rst three e⁄-
cacymeasures as follows:
Onwaking, each patient recorded a score (0^5) in the
dailyrecordcard thatre£ected the degree towhich their
night had been subjectively disturbed by symptoms of
COPD. A symptom-free night was de¢ned as one during
which the patient reported no symptoms (symptom
score in dairy card = 0). Patients who withdrew early
due to COPD-related adverse events or lack of e⁄cacy
were assumed to have had no symptom-free nights from
the time of withdrawal to the scheduled end of
treatment. Patients withdrawn for other reasons were
assigned a rate for each day after withdrawal equal
to the mean rate for their treatment arm on that
particular day.
Each evening, patients recorded a score (0^5) in the
diary card which re£ected the extent to which their day
had been subjectively a¡ected by COPD symptoms.The
symptom scores were recorded as follows: 0=no symp-
toms atrestor on exertion; 1=no symptoms atrest; but
symptoms on moderate exertion; 2=no symptoms at
rest but symptoms on mild exertion; 3=minimal symp-
toms at rest; 4=moderate symptoms at rest; 5= severe
symptoms at rest, unable to carry out any activity re-
quiringexertion.For eachpatient, thepercentage ofdays
with a daytime symptom score less than 2 was calcu-
lated.Patientswhowithdrewearlydue toCOPD-related
adverse events or lack of e⁄cacy were assumed to have
had no days with a daytime symptom score less than 2
from the time of withdrawal to the scheduled end of
treatment. Patients who withdrew for other reasons
were assigned a rate for each day after withdrawal that
was equal to the mean rate for their treatment arm on
that particular day.
Treatment e⁄cacy was also based on the percentage
of successfully treated patients. A patient was
considered successfully treated if the FEV1 percentage
normal predicted at the end of the treatment period
was greater than the FEV1percentage normal predicted
at baseline by at least 15%. Patients who withdrew early
due to COPD-related adverse events or lack of
e⁄cacy were considered unsuccessfully treated at the
end of treatment. Patients withdrawn for other reasons
were considered successfully treated at the end of
treatment.
Health status analysis
Health status was assessed at baseline and16 weeks on a
subgroup of patients using the St George’s RespiratoryQuestionnaire (SGRQ). In order to minimise response
bias, the questionnaireswere completed separately from
other data collection activities. The SGRQ is self-admi-
nistered in adult populations and is applicable to both
¢xed and reversible airway obstruction. It contains 50
items with 76 weighted responses in three domains
(11,12).The symptomdomainmeasures distress due to re-
spiratory symptoms, the activity domain measures the
e¡ect on mobility and physical activity, and the impact
domainmeasures thepsychosocial impact of the disease.
Scores range from 0 to 100 with lower scores indicating
better health status. A change of score of four points is
considered to be clinically signi¢cant (11).
Economic analysis
The economic analysis was conducted from theperspec-
tive of the healthcare pay or using U.K. costs. Reporting
of resource use was based upon resources used during
the treatment phase of the study only.The following re-
source utilisation measures were evaluated: COPD-re-
lated accident and emergency room visits; COPD-
related outpatient hospitalisations; COPD-related inpa-
tient hospitalisations; COPD-related GP contacts; study
drugs; rescue medications and COPD-related concur-
rentmedication.
Patients whowithdrew from the study were assumed
to use the dailymeanrate ofresource (drugor non-drug)
of the treatment arm from the day of withdrawal to the
scheduled end of study period.
Analysis
For the percentage of symptom-free nights and percen-
tage of days with daytime score less than 2, comparison
of treatments wasmade using theVan Elteren extension
to theWilcoxon rank sum test strati¢ed by country.The
analysiswas summarisedusingmeandi¡erences,P-values
and 95% con¢dence intervals (CI).These 95%CIwere ob-
tainedusing anunstrati¢edWilcoxon rank sum test. Sta-
tistical testing was two-sided and performed at the 0.05
signi¢cance level. For successfully treated patients, com-
parison between treatments was made using the Co-
chran^Mantel^Haenszel test controlling for country.
Statistical testing was two-sided and signi¢cance ac-
cepted at Po0.05.
Changes in health status were estimated by the num-
ber of successfully treated patients at the end of the
study. A patient was de¢ned as successfully treated if
the total score at study end decreased by four or more
points from baseline. In addition, patients assessed the
e⁄cacy of their medication throughout the study. Com-
parisons between groups at the end of the study were
made using the Cochran^Mantel^Haenszel test con-
trolling for cluster of country.
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week and at the end of the study period.The di¡erence
in the total costs between treatments was summarised
using means and a 95% CI derived using the non-para-
metric bootstrap method (13). The cost^ e¡ectiveness
analysis used the e¡ectiveness and resource use data
from all countries combined and the unit costs of direct
resources in the U.K. No statistical comparisons be-
tween treatment groups were performed. Average
cost^ e¡ectiveness ratios were calculated by dividing to-
tal direct medical costs of all patients by the four out-
come measures. Incremental cost^ e¡ectiveness ratios
(ICER) were calculated by subtracting placebo direct
medical costs from salmeterol. This term was then di-
vided by the di¡erence in e¡ect between salmeterol and
placebo on the three e¡ectiveness measures. for the
ICER were calculated using the non-parametric boot-
strapmethod (13).
RESULTS
Treatment e⁄cacy
The e⁄cacy of treatment with salmeterol over the 16-
week treatment period is shown in Fig. 1. Patients who
received salmeterol 50mcgb.i.d. had a greatermeanper-
centage of symptom-free nights than did those patients
who received placebo (59.9 vs. 45.8%, Po0.001). There
was no di¡erence in the percentage of days with a symp-
tom score less than 2 (mean percentage 46.1 vs. 40.2%,
P=0.9).Morepatients in the salmeterol treatment group
were successfully treated than in theplacebo arm (415%
increase in predicted normal FEV1 from baseline, 32 vs.
15%, Po0.001).TABLE 2. Mean (standard deviation) total direct medical costs
weeks
Hospital contacts
A&E
Inpatient
Total costof hospital contacts
Hospital as an outpatient
GPcontacts
Medication costs
Studydrug
Rescuemedication
COPD-related concurrentdrugs
Total costofmedications
Total directmedical costs
Di¡erence intotal cost per patient (salmeterol ^ placebo)
*Ninety-¢ve percent CI calculatedusing the bootstrapmethoHealth status e¡ects
The percentage of patients whose health status im-
provedwas higher in the group compared to the placebo
group. Fifty-nine per cent of patients in the salmeterol
group demonstrated a decrease of 4 or more points on
the SGRQ total score compared to their baseline score.
In the placebo group, the percentage of patients that de-
monstrated a similar level of improvementwas only 38%.
A 22% di¡erencewas demonstrated (95% CI 8, 35%).
At the end of the study patients were asked to assess
the overall e⁄cacy of theirmedication. In the salmeterol
treatment group, 66% of patients rated the e⁄cacy of
theirmedication as e¡ective compared to 45% in thepla-
cebo group (Po0.001). Of the patients who rated their
medication as e¡ective, a signi¢cantly higher proportion
of patients also had a clinically signi¢cant improvement in
health status compared with the placebo group (63 vs.
45%, P=0.04).
Resource utilisation and costs
Resource use and costs may be broken down into three
categories: direct medical, direct non-medical and indir-
ect costs. Direct medical costs include costs related to
the medical management of a disease (e.g. hospitalisa-
tions, consultations and medications) are the only costs
included in the analysis. The mean total direct medical
costs per patient are shown inTable 2. Mean daily costs
in the salmeterol treatment groupwere d1.72 compared
tod0.91for theplacebo group.Over theperiod of1week,
total direct medical costs were d12.02 in the salmeterol
treatment group compared with d6.39 in the placebo
group.in U.K. pounds per patient in the treatment of COPD over16
Salmeterol 50mcgbid Placebo
0.43 (6.48) 1.30 (11.24)
48.3 (283.68) 62.95 (384.63)
49.26 (286.62) 64.26 (386.80)
2.04 (12.87) 1.50 (10.02)
6.89 (14.47) 9.29 (17.72)
110.76 0.00
2.62 (2.45) 3.55 (2.72)
20.82 (27.25) 24.13 (38.06)
134.17 (27.67) 27.55 (38.25)
192.37 (292.39) 102.26 (398.47)
90.10 (95% CI 20.09,154.11)*
d.
24 RESPIRATORYMEDICINEOver the16-week studyperiod, patients in the salme-
terol arm had lower hospital costs than those who re-
ceived placebo. Hospital costs were de¢ned as the sum
of accident and emergency (A&E) visits and hospital ad-
missions.Patients in the salmeterol armhad amean total
hospital cost of d49.26 per patient whilst patients in the
placebo armhad amean total hospital cost of d64.26 per
patient.The use of A&E and hospital admissions was low
for the patients in each treatment group, because most
did not use these resources as highlighted by the large
standard deviations. The mean cost for outpatient visits
was similar for the two treatmentgroups.Themean cost
for GP contacts and COPD-related medications was
lower in the salmeterol arm. The total cost of medica-
tions indicates that those patients who received salme-
terol had higher associated medication costs than those0
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FIG. 1. E¡ectiveness results for four endpoints. *Signi¢cantdi¡er
TABLE 3. Cost-e¡ectiveness ratios
Cost per symptom-free night Mean
Costperdaywith daytime symptom scoreo2 Mean
Costper successfully treatedpatient (FEV1criterion)
b Mean
Dailycost perhealth status improvedpatient (SGRQ)c Mean
aA patient was successfully treated if the FEV1 percentage no
normalpredicted at baseline (visit 3) by15%.
bNinety ¢ve percentcon¢dence intervals (CI) calculatedusing t
cApatientwas successfully treated if the total score atweek16 w
Abbreviations: ICERF incremental cost^e¡ectiveness ratio.who received placebo.The mean total cost over the16-
week period was d102.26 for the placebo group com-
paredwith d192.37 for the salmeterol group, a di¡erence
of d90.10 (95% CI d20.09^d154.11).
Average and incremental cost^ e¡ectiveness ratios
were calculated. To examine the net costs and bene¢ts
of salmeterol treatment over placebo treatment, an in-
cremental analysis was performed. Cost^ e¡ectiveness
ratios were calculated for the proportion of symptom-
free nights (Table 3). The mean cost-e¡ectiveness ratios
were lower for placebo than salmeterol, a ¢nding that
was maintained in a sensitivity analysis. The ICER, used
to assess the additional cost required to achieve one ex-
tra symptom-free night, was d5.67 (bootstrap CI d1.85^
d14.06). Although salmeterol has a higher cost, it ismore
e¡ective than existing treatment as measured by <2
15% increase in
FEV1
Decrease > 4 on
SRQ total score
eness measure 
terol Placebo
*
*
ence (Po0.05).
Salmeterol 50 mg Placebo
cost^e¡ectiveness ratio 2.87 2.00
ICER (95% CI)a 5.67 (1.85,14.06)
cost^e¡ectiveness ratio 3.68 2.28
ICER (95% CI)a 12.33 (-54.99,75.84)
cost^e¡ectiveness ratio 5.39 6.31
ICER (95% CI)a 4.62 (1.08,10.40)
cost^e¡ectiveness ratio 2.51 1.40
ICER (95% CI)a 4.44 (1.85,11.78)
rmal predicted at week16 was greater than FEV1 percentage
he bootstrapmethod.
as decreased by 4 ormore points frombaseline.
ECONOMICEVALUATIONOFSALMETEROLINCOPD 25symptom-free nights.When both cost and e¡ect are as-
sessed between groups, the cost of achieving an extra
nightwithout symptoms is quitemodest. In otherwords,
in the primary analysis, itwould cost d5.67 to obtain one
extra symptom-free night compared to existing treat-
mentwith the additional cost lying somewhere between
d1.85 and d14.06 per extra symptom-free night.
The cost^ e¡ectiveness ratios for themeasure of days
with a daytime symptom score o2 are shown in
Table 3.The ICER, or the cost of an additional day where
the symptom score is o2, was d12.33. This is the addi-
tional cost that must be paid over and above existing
treatment in order to obtain an additional day when the
symptom score iso2. It is important to note, however,
that therewas no signi¢cant di¡erence between the two
treatmentgroupswith respect to this e¡ectivenessmea-
sure (Fig.1).
The cost^ e¡ectiveness ratios based on the propor-
tion of successfully treated patients are given inTable 3.
Analysis of using the number of patients achieving15% in-
crease in FEV1 (as percentage of predicted normal) from
baseline gave an incremental cost^ e¡ectiveness ratio of
d4.62 This implies that for each extra patient to be
classed as being successfully treated using this criterion,
therewouldbe an additional cost of d4.62 (95%CI d1.08^
d10.40). The analysis of the cost per health status im-
provedpatientbased on the SGRQ shows that the incre-
mental cost^ e¡ectiveness ratio was d497.47 over the16
week time period (95% CI d210.13^d1481.09). On a daily
basis this translates to d4.44 (95% CI d1.85^d11.78).
DISCUSSION
To date few studies have examined the clinical and eco-
nomic impact of treatments in COPD.This study has ex-
amined the use of a long-acting agonist in COPD and is
the ¢rst to demonstrate that signi¢cant improvements
in health and quality of lifemay be obtained atmoderate
cost.
Several endpointswere examineddue to the complex-
ity of COPD and the fact that there is no one agreed out-
come of interest which captures the full range of
treatment bene¢ts. The parameter chosen to de¢ne
successfully treated patients was FEV1, as it is widely ac-
cepted in clinical trials.The SGRQwas selected as amea-
sure of patient health status, as it is a measure that has
been used in several trials to evaluate patient su¡ering in
chronic lung disease. As such this study has sought to
quantify both objective clinical measures as well as sub-
jective health status measures.The impact of salmeterol
on health status was explored more fully in a previous
study (9).This study found that the gains in health status
in patients taking 50mcg twice daily exceeded the esti-
mated threshold for clinical signi¢cance. On the SGRQ,
improvements were observed in the Impacts domain.Similar trends were noted for the physical functioning,
role physical and vitality domains of the SF-36. In the cur-
rent study, signi¢cantly more patients in the salmeterol
group had improvements in both clinical and health sta-
tus parameters than in the placebo group. Therefore,
from a clinical and patients’ perspective, the salmeterol
50mcg treatment group obtained health bene¢ts above
those found in placebo patients.
In this case, the total treatment costs were slightly
higher for salmeterol 50mcg compared to placebo.
Whether the additional bene¢t of salmeterol
treatment is worth the additional costs is not entirely
an empiricalmatter: the physician’s perception of the va-
lue of the treatment as well as the patient’s own experi-
ence with the disease need to be considered. The
results of this study show thatobjective clinical improve-
mentwas achieved aswell as improvements inmore sub-
jective domains of health status for the patients on
salmeterol. These improvements occurred with only a
slight increase in cost. Salmeterol costs were d0.81more
per day compared to placebo to achieve the additional
clinical and health status bene¢ts.
Whether salmeterol is worth the additional expense
can be partially addressed by comparing the results to
other published cost^ e¡ectiveness studies in COPD
and to studies in other disease areas. Unfortunately,
there have been few pharmacoeconomic studies in
COPD.One study (14) found that (2-agonist therapy in
conjunction with corticosteroid therapy resulted in im-
proved health outcomes at a small increase in cost com-
pared to 2-agonist therapy alone. The addition of an
inhaled corticosteroid to a 2-agonist resulted in net
additional healthcare costs of $201 per patient year
compared to a 2-agonist alone. A retrospective study of
salmeterol in patients with asthma found its use
justi¢ed based on its pharmacoeconomic pro¢le. Medi-
cation costs were higher for salmeterol, but the
costs were almost completely o¡set by savings in consul-
tations (15).
The results of this study are also consistent with
a previous investigation of salmeterol 50mcg b.i.d.
compared to oral, sustained release theophylline b.i.d.
In this study both drugs improved health status as mea-
sured by the SF-36; however, salmeterol had more
positive e¡ects on more domains than theophylline pa-
tients (16).
As this study was conductedover a 4-month timeper-
iod as part of a clinical trial, it was not possible to incor-
porate an endpoint that would facilitate comparisons
across disease areas. Thus, a quality-adjusted life year
was not calculated as part of this study. In order to facil-
itate comparisons with other disease areas the clinical
trial or a new study would need to be conducted that
was at least12months in length andused a generic utility
measure such as theHealthUtilities Indexor a directuti-
lity assessment techniques such as the standard gamble.
26 RESPIRATORYMEDICINEThis study did not address the indirect costs (or
productivity losses or gains) associated with the treat-
ments. The valuation of productivity changes is contro-
versial in economic evaluations. The e⁄cacy data
suggest; however, that if the indirectcostswere included
in this evaluation, further bene¢ts may have been de-
rived. Given the positive relationship between perfor-
mance and health status, further savings in societal
costs may occur with the use of salmeterol in patients
with COPD.
This study was representative of the patient popula-
tion with COPD and the results are generalisable across
patients with the condition. However, it is essential to
note two important limitations: the relatively short time
horizon of the study and the presence of a clinical proto-
col that may have enhanced patient compliance. These
factors prevent broad statements from being made
about the cost^ e¡ectiveness of salmeterol in general
practice. The presence of protocol-induced visits may
lead to increasedmonitoring of patients with associated
improvements in health behaviour and compliancewhich
may lead to anunderestimate of costs compared towhat
would occur in a more naturalistic setting. The
short time period, in particular, places important limita-
tions on the accuracy of the cost estimates as expensive
hospitalisations may have occurred outside of the study
period.
In this study, the clinical results were consistent
with health status results and patient assessments. Im-
provements in FEV1weremirrored by improvements on
the SGRQ and on self-rated assessments of e⁄cacy.
The results from our study show that salmeterol is
more e¡ective than placebo at improving symptom-free
days and nights, and these results are re£ected in the
patients’ responses to the health status questions.
Overall, this study has demonstrated that the use of sal-
meterol 50-mcg over a 16-week period provided im-
provements in health status and health-related
health status with only a modest increase in direct
medical cost.REFERENCES
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